Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — Q2 FY2026 Earnings Presentation
19 slides from Zim Laboratories's earnings presentation, Nov 12, 2025
Slide 1: Cover letter to BSE and NSE under Regulation 30
Ref No.: ZLL/CS/BSE/NSE Date: 12.11.2025 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) D
Slide 2: Zim Laboratories Limited Earnings Presentation Q2 & H1FY26
ZIM LABORATORIES LIMITED E A R N I N G S P R E S E N TAT I O N Q2 & H1FY26 www.zimlab.in
Slide 3: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 4: Content
CONTENT 01 Q2 & H1FY26 - HIGHLIGHTS 02 MANAGEMENT’S PLAN FOR CAPA REMEDIATION 03 BUSINESS MIX 04 R&D & INNOVATION 05 SHAREHOLDING 3
Slide 5: Q2 & H1FY26 Highlights
Q2 & H1FY26 HIGHLIGHTS Financial Highlights (Q2FY26) Financial Highlights (H1FY26) Total Operating Income stood at Total Operating Income at ₹1,605 Mn, ₹887 Mn in Q2FY26, marking a declined by 7.8% in H1FY26 vs ₹1,740 23.6% increase over the previous Mn in H1FY25 quarter Q1FY26 EBITDA at ₹78 Mn, up
Slide 6: Management's Plan for CAPA Remediation
MANAGEMENT’S PLAN FOR CAPA REMEDIATION Q3 FY 26 Q4 FY26 Q1 FY27 Q2 FY26 June / July EU GMP Inspection Submission of CAPA Progress Submission of CAPA Progress Registration of Products in for upto October 2026 Alternate Markets Onboarding External Validation by Consultants Consultant for CAPA Plan App
Slide 7: Financial Performance – H1FY26
FINANCIAL PERFORMANCE – H1FY26 Total Operating Income (Rs Mn) EBITDA (Rs Mn) & EBITDA margin Profit After Tax (PAT) (Rs Mn) & PAT margin 11.4% 8.4% 1.9 % -1.4% 33 1740 199 1605 135 H1 FY25 H1 FY26 (23) H1 FY25 H1 FY26 H1 FY25 H1 FY26 o Total Operating Income at ₹1605 Mn in H1FY26, reflecting a degro
Slide 8: Financial Performance – Q2 FY26
FINANCIAL PERFORMANCE – Q2 FY26 Total Operating Income (Rs Mn) EBITDA (Rs Mn) & EBITDA margin Profit After Tax (PAT) (Rs Mn) & PAT margin 11.8% 7.9% 8.8% 2.6% -2.6 % -0.5% 24 922 887 718 109 (4) Q2 FY 25 Q1 FY 26 Q2 FY 26 78 (19) 57 Q2 FY 25 Q1 FY 26 Q2 FY 26 Q2 FY 25 Q1 FY 26 Q2 FY 26 o Total Opera
Slide 9: Business Mix
BUSINESS MIX Pharma Revenue (₹ Mn) & Contribution to Total Nutra Revenue (₹ Mn) & Contribution to Total Operating Income (%) Operating Income (%) 82% 83% 33% 77% 78% 71% 29% 67% 23% 22% 18% 17% 891 266 268 739 732 224 654 196 552 560 158 155 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q1FY25 Q2FY25 Q3
Slide 10: Revenue Mix
REVENUE MIX 27, 3% 32, 4% 59, 4% 48, 3% 127, 14% 214, 12% 227, 14% 137, 15% Q2FY25 Q2FY26 H1FY25 H1FY26 1467, 84% 1330, 83% 758, 82% 728, 82% Export Domestic Deemed Export Export Domestic Deemed Export Export Domestic Deemed Export Export Domestic Deemed Export Numbers in ₹Mn o Q2FY26: Export busine
Slide 11: Innovative Product Contribution
INNOVATIVE PRODUCT CONTRIBUTION (NIP + OTF) Revenue (₹ Mn) & Contribution to Total Operating Income (%) 21.8% 17.8% 13.5% 14.0% 12.7% 178 9.2% 164 9.5% 147 8.5% 135 109 112 6.3% 82 81 46 Q2 FY 24 Q3 FY 24 Q4 FY 24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 o Q2FY26: NIP + OTF operating income g
Slide 12: Advancing Innovation: NIP Product Pipeline (EU/UK)
ADVANCING INNOVATION : NIP PRODUCT PIPELINE (EU/UK) Formulation Regulatory MA Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Received Supplies Product 1 Urology Product 2 Gastrointestinal Product 3 Anti – Coagulant Di-Methyl Fumarate CNS Product 5 Urology Prod
Slide 13: Advancing Innovation: OTF Product Pipeline (EU/UK)
ADVANCING INNOVATION : OTF PRODUCT PIPELINE (EU/UK) Formulation Regulatory MA Commercial Product Therapy Area Market Review Validation BE Studies Development Filing Received Supplies Rizatriptan CNS Sildenafil Erectile Dysfunction Product 3 CNS Product 4 Erectile Dysfunction Buprenorphine Opioid De
Slide 14: R&D Driving Product Innovation
R&D DRIVING PRODUCT INNOVATION R&D Expense Mix % of Total R&D Investment and Total R&D Investment as % of Total Operating Income 89 2 75 9.7% 9.7% Capital Expenses on BE study, 29% registrations etc 37% R&D Team Post- PhDs 1% Size Graduates 2% Capital Expenses on Infrastructure & Equipment 7 4 ₹155
Slide 15: Income Statement
INCOME STATEMENT Particulars (₹ Mn) Q2FY26 Q2FY25 YoY% H1FY26 H1FY25 YoY% Total Operating Income 887 922 (3.7%) 1605 1,740 (7.8)% Other Income 20 13 53.8% 35 23 52.2% Total Income 907 935 (2.9%) 1640 1,763 (7.0%) EBITDA 78 109 (28.4%) 135 199 (32.2%) EBITDA % 8.8% 11.8% (303bps) 8.4% 11.4% (302bps)
Slide 16: Balance Sheet
BALANCE SHEET Particulars (₹ Mn) H1FY26 FY25 FY24 FY23 FY22 Gross Block – Tangible & Intangible Assets 3,526 3,453 3,089 2,257 1,920 including WIP Net Block – Tangible & Intangible Assets 2,334 2,347 2,031 1,357 1,174 including WIP Other Non- Current Assets 99 60 161 150 121 Current Assets 2,268 2,3
Slide 17: Key Financials
KEY FINANCIALS Gross & Net Fixed Assets (₹ Mn) Gross Current Assets (₹ Mn) & % of Total Assets 62% 3,453 3,526 56% 3,089 51% 49% 48% 2,257 2,347 2,334 1,920 2,031 1,357 1,174 FY22 FY23 FY24 FY25 H1FY26 FY22 FY23 FY24 FY25 H1FY26 Gross Fixed Assets Net Fixed Assets Net Worth (₹ Mn) Total Borrowing (₹
Slide 18: Shareholding
SHAREHOLDING Ownership % (September 2025) Traded Volume (In K) BSE+NSE 5% 33% 26,593 43% 18,435 16,660 14,093 14,104 11,313 12% 5,734 7% Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Promoter HNI Body Corporates Other Public Shareholding • Number of Shareholders in H1FY26 accounted to 17.4K NRI &
Slide 19: Investor Relations Company Contact
Investor Relations Company Contact Mr. Zain Daud Ms. Sheetal Khanduja Address Zim Laboratories Limited Go India Advisors Sadoday Gyan (Ground Floor), Opposite NADT, Nelson Square, zain.daud@zimlab.in sheetal@GoIndiaAdvisors.com Nagpur, Maharashtra 440013 M:+91 9022434631 M:+91 97693 64166 www.zimlab